New Capital, New Trajectory: IHC's First Full Quarter
With ₹8,850 Cr in fresh capital from IHC now deployed and a new growth roadmap in place, Sammaan Capital's first full quarter under its new promoter tests whether the transformation thesis—doubling margins, scaling AUM to ₹1.3–1.5L Cr by FY29—can move off the page.
For Sammaan Capital, AUM trajectory and margin burn define the quarter. After May's transformational IHC close—bringing ₹8,850 Cr and a new 28.39% promoter stake—the Street wants to see disbursement momentum, evidence of blended cost-of-funds compression (guidance: 250 bps improvement by plan), and the pace of capital deployment into the ₹1.3–1.5L Cr AUM target by FY29. Q1 Q1 FY27 is the first full quarter under new ownership; execution on both growth and margin will calibrate Street confidence in the five-year roadmap.
What to Expect
~₹48,000–49,500 Cr
on-plan 8–12% YoY growth, assuming steady disbursement pace and capital deployment
~250–350 bps improvement track
guided compression of 250 bps by FY29; Q1 should show early momentum as IHC funding costs lower blend rate
~₹8,000–9,500 Cr
home loans, LAP, and construction finance; watch for product mix shift post-IHC
~1.5–2.0% slippage
stable profile expected; GNPA/NNPA ratio to track; regulatory headwinds remain a watch
A strong print: AUM growth in double digits (10%+ YoY), early signs of net interest margin improvement (even 50–100 bps guidance reduction YoY is a green flag), disbursements in line with or ahead of quarterly run-rate, and GNPA/NNPA stable to tightening. Management confident on deployment of warrant-conversion capital (₹3,198 Cr) and timing of scheme of arrangement close (Sept AGM). A weak print: AUM growth below 8% YoY (stalls the momentum narrative), margin expansion absent or compressed further YoY (signals higher-than-guided borrowing costs or price competition), disbursements miss by >15%, or uptick in slippages (>2.5%). Any guidance walk on the ₹1.3–1.5L Cr AUM target for FY29 would reset Street expectations.
On Track?
Yes, in terms of capital and ownership transformation. The IHC close in May and prompt board refresh anchored the new era. What's unproven: margin delivery. FY26 (pre-close) saw NIM pressure as interest-rate cycle tightened; IHC's lower funding costs and diversified funding mix (bonds, IHC balance sheet) should reverse this by mid-FY27. Q1 should show the lag closing: if management guided 250 bps improvement over the plan's full tenure, achieving 30–50 bps in Q1 FY27 vs Q1 FY26 would signal confidence. Watch also for AUM deployment velocity—₹8,850 Cr is a war chest; Q1 must show meaningful uptake into home loans and LAP. Disbursement pacing will calibrate Street comfort with FY27 guidance.
What the Street Says
Since Last Quarter
The core narrative: IHC closes, ownership transforms. (May 2026). International Holding Company PJSC completed ₹8,850 Cr investment; Avenir Investment (IHC affiliate) became promoter at 28.39%. Further ₹3,198 Cr warrant conversion pending. Board refreshed; CEO Gagan Banga positioned transformation plan—₹1.3–1.5L Cr AUM by FY29, net margins to double, 250 bps borrowing-cost improvement.
Capital structuring: (May–Aug 2026). Allotted ₹1,400 Cr in non-convertible debentures (Series I ₹800 Cr, Series II ₹600 Cr, Jul 2026). Tender offer for USD 350M bonds (9.70% due 2027) to buyback up to USD 18M (closed Aug 2026). Authorized ₹10,000 Cr fundraise via bonds/debentures. Routine debt management.
Legal & governance: (Jun–Jul 2026). NCLT approved first motion application for scheme of arrangement (Jun 2026); clarification application allowed (Jul 2026). AGM scheduled Sept 10, 2026 for final shareholder sign-off. No operational red flags; formalities on track.
Watch on Result Day
1 · AUM & Disbursement Pace
Is growth sustaining double-digit YoY momentum? Disbursements in line with or ahead of quarterly run-rate? Early evidence of capital deployment from IHC ₹8,850 Cr? Miss here resets the whole story.
2 · NIM & Margin Trajectory
Is net interest margin showing any compression relief vs prior quarter and prior year? Even 25–50 bps YoY improvement signals early wins from IHC funding mix. Flat or worsening NIM puts pressure on guidance.
3 · Slippage & Asset Quality
GNPA/NNPA ratio: stable to tightening is the baseline. Any uptick >2.5% GNPA would flag macro headwinds or credit-loss acceleration. Watch management commentary on portfolio stress.
4 · FY27 Guidance Reaffirm
Does management stick to ₹1.3–1.5L Cr AUM by FY29, 250 bps NIM improvement, and margin-doubling narrative? Any walk on growth or margin would reset Street. Clarity on warrant-conversion timing and fresh fundraise plan also matters.
Sammaan Capital's Q1 FY27 result is the first earnings print of the new era. Street consensus is cautiously bullish—IHC capital + offshore funding unlock a step-change in margins and growth. But it's a hypothesis, not a fact. Disbursement momentum, NIM relief, and steady AUM growth are the proof points. Miss on margin or AUM, and the 250 bps guidance becomes a distraction rather than an anchor. The setup favors the bull, but Q1 must deliver.
Key dates: Result on August 13, 2026. AGM for scheme ratification Sept 10, 2026.
Sammaan Capital beats street with ₹243 Cr PAT; YoY revenue, profit still down 31%, 27%
PAT -27.22% YoY · revenue -31.18% · margins expanding · beat vs street
₹1,651.93 Cr
-31.18% YoY
₹243.3 Cr
-27.22% YoY
14.46%
+0.6pp YoY
₹2.13
Sammaan Capital (formerly Indiabulls Housing Finance) posted consolidated PAT of ₹243.30 Cr for Q1 FY27 (quarter ended June 30, 2026), comfortably ahead of Street estimates of roughly ₹147–187 Cr (Univest), and a sharp reversal from the ₹8,101.41 Cr consolidated loss booked in Q4 FY26. Standalone PAT was ₹225.60 Cr (basic EPS ₹1.94) against consolidated basic EPS of ₹2.13. On a YoY basis — the primary lens for judging the quarter — the print is still a decline: consolidated revenue from operations fell 31.2% to ₹1,651.93 Cr (from ₹2,400.33 Cr) and PAT fell 27.2% (from ₹334.30 Cr), matching our own event feed's same-day read of "YoY revenue, profit still down ~31%, 27%."
Q1 FY-2027 vs prior quarters
The QoQ swing back to profit is explained by the base quarter, not new strength: Q4 FY26's loss was driven by a one-off ₹6,499.17 Cr exceptional item plus a spike to ₹2,958.08 Cr in impairment provisioning, both tied to the Board's March 2026 decision to reclassify ₹14,953 Cr of non-core "Identified Exposures" (stressed, long-tenured loans and investments) from Hold-to-Collect to Hold-to-Sell for ARC sale and resolution. That cleanup is now largely behind the company — this quarter's impairment line flipped to a net write-back of ₹240.47 Cr (₹232.05 Cr standalone) — and net profit margin actually improved YoY to 14.46% from 13.88% even as the book shrank. Asset quality on the remaining book is clean: Gross NPA 0.22%, Net NPA 0.17%, CRAR 20.06%, LCR 127% (standalone), none of which points to fresh stress.
The stock went into the print at ₹161.8, down 1.1% over the past month of trading.
Management deferred specific revenue guidance pending the closure of the transformative IHC investment. Post-transaction, the company plans a strategic shift to a 'full suite NBFC,' targeting a 4.0-4.5x leverage ratio by 2030, a 270 bps reduction in cost of funds by March 2027, and a 30-40% dividend payout ratio. In th
All four rating agencies covering the company — S&P Global (international rating upgraded to 'BB-'/Stable), CRISIL, CARE and ICRA (each to AA+/Stable) — upgraded ratings this quarter, explicitly citing the March 2026 IHC (International Holding Company PJSC, Abu Dhabi) capital infusion of ₹8,850 Cr and improved capitalisation; this is the tailwind management's FY27 cost-of-funds target (a 270 bps cut) leans on, though finance costs (₹1,335.26 Cr consolidated) haven't meaningfully re-rated yet. The filing itself carries no MD&A or guidance commentary, so this print cannot be graded against a formal FY27 outlook restatement — the 4.0-4.5x leverage and 30-40% dividend-payout targets on record are from the Q3 FY26 concall and remain unconfirmed here. Corporately, the quarter saw H.E. Dalia Khorshid (Avenir/IHC nominee) join the board, a ₹1,400 Cr NCD allotment, and continued progress on the Sammaan Finserve demerger (shareholder meeting convened for September 10, 2026) and a six-subsidiary amalgamation (second NCLT motion still pending since June 2025).
W1
Cost-of-funds/NIM trajectory: the 270 bps cut target by March 2027 is now backed by AA+/Stable ratings across CRISIL/CARE/ICRA — watch whether the ₹1,335.26 Cr consolidated finance-cost line starts declining next quarter.
W2
Sammaan Finserve demerger outcome at the September 10, 2026 shareholder meeting will determine consolidation scope from Q2/Q3 FY27.
W3
No AUM/disbursement/NIM figures disclosed this quarter — confirm whether the post-cleanup loan book (₹37,021.94 Cr standalone per the Aug 13, 2026 security-cover certificate) begins growing toward the FY29 AUM targets.
Consolidated includes 9 subsidiaries+trust (₹178.86 Cr revenue, ₹17.70 Cr PAT per auditor note); Q4FY26 base was distorted by a ₹6,499.17 Cr exceptional item plus an impairment spike from the non-core-book reclassification, so patQoQPct is left null as not meaningful; standalone (₹225.60 Cr) vs consolidated (₹243.30 Cr) PAT track the same YoY-decline direction, no material divergence.